Conotoxins and Ziconotide: Cone-Snail Venom Peptides Explained
Venom-derived peptides
Conotoxins are small, disulfide-rich peptides made by cone snails, and one of them, ziconotide, became an approved drug for severe chronic pain. Each snail’s venom contains a cocktail of these peptides, and different families switch off different ion channels and receptors on nerve and muscle cells. They are among the best examples of how a natural toxin can be turned into a precise research tool and, rarely, a medicine.
What are conotoxins?
Cone snails hunt with a harpoon-like tooth that injects venom. The venom is a complex mix of short peptides, typically short and tightly folded by several disulfide bonds (see disulfide bonds in peptides). A 1985 Science paper from Baldomero Olivera’s laboratory, “Peptide neurotoxins from fish-hunting cone snails”, is one of the early landmark descriptions of these molecules, and a 1987 Biochemistry paper from the same group showed that an omega-conotoxin from Conus magus could discriminate between calcium-channel subtypes.
Conotoxins are grouped by the Greek letter that names the target they act on. Alpha-conotoxins are competitive antagonists of the nicotinic acetylcholine receptor. Mu-conotoxins target voltage-gated sodium channels, preferentially in skeletal muscle. Omega-conotoxins inhibit N-type calcium channels. Delta-conotoxins slow the fast inactivation of sodium channels, and kappa-conotoxins inhibit potassium channels.
How ziconotide is studied to work
Ziconotide is the synthetic equivalent of omega-conotoxin MVIIA from Conus magus. The UniProt entry (P05484) shows that the mature peptide is residues 46–70 of a 71-residue precursor: 25 amino acids, with a C-terminal amide and three disulfide bridges (Cys1–Cys16, Cys8–Cys20 and Cys15–Cys25 in mature numbering) forming a compact knottin fold. The FDA label describes it as a hydrophilic, polybasic 25-residue peptide with a molecular weight of 2,639 Da.
The target is the N-type voltage-gated calcium channel, CaV2.2 (gene CACNA1B), which sits on nerve terminals and helps trigger neurotransmitter release. UniProt lists reported IC50 values for CaV2.2 block spanning 0.67 to 208 nM depending on the assay. In 2021 a Nature paper by Gao, Yao and Yan reported cryo-electron-microscopy structures of human CaV2.2 with ziconotide bound, showing the peptide acting as a pore blocker. According to the FDA label, ziconotide binds N-type channels on primary nociceptive afferents in the spinal dorsal horn and reduces excitatory neurotransmitter release, although the label notes that the mechanism in humans has not been established.
Reported effects in the research literature
The research value of conotoxins is their selectivity. Because each family hits a defined channel or receptor, they are widely used as molecular probes to tell channel subtypes apart, which is exactly what the 1987 omega-conotoxin work did for calcium channels. Ziconotide is the clinical expression of that selectivity: blocking one channel on pain-signalling neurons without a broad effect on others.
What the human evidence and regulatory status show
Ziconotide is sold in the United States under the brand name Prialt, first approved in 2004. Its indication is the management of severe chronic pain in adults for whom intrathecal therapy is warranted and who are intolerant of or refractory to other treatment. It is given by continuous intrathecal infusion, that is, into the fluid around the spinal cord through a pump, and is not for intravenous use. The label carries a boxed warning that severe psychiatric symptoms and neurological impairment may occur, and the drug is contraindicated in people with a pre-existing history of psychosis. The label gives a CSF terminal half-life of about 4.6 hours. A 2004 review by Miljanich in Current Medicinal Chemistry covers the drug’s development.
That narrow, hospital-managed profile illustrates a general point from peptides versus small molecules: a peptide that is highly target-selective may still need an unusual route of delivery and carry serious dose-related adverse effects.
Handling, storage and reconstitution (research context)
Conotoxins used as laboratory reagents are normally supplied as lyophilised peptides (see why peptides are freeze-dried) and handled with standard sterile technique. The reconstitution calculator and concentration converter cover the arithmetic; the reconstitution guide and sterile technique guide cover practice. Because many conotoxins are potent neurotoxins, laboratory safety data sheets must be followed, and unit confusion should be avoided (IU versus mL).
Cautions and considerations
This article is educational. Venom peptides are not supplements or research shortcuts: ziconotide’s own label restricts its use to a specialist intrathecal setting because of psychiatric and neurological risk. Nothing here describes or encourages human use of any conotoxin.
Frequently asked questions
What is the difference between a conotoxin and ziconotide?
Conotoxin is the general name for peptides from cone-snail venom. Ziconotide is the synthetic version of one of them, omega-conotoxin MVIIA from Conus magus.
Why are conotoxins so stable?
Their disulfide bonds lock the peptide into a compact knot-like fold, which restricts flexibility; the general role of disulfide bridges is covered in our disulfide-bond guide.
Why is ziconotide given into the spinal fluid?
The FDA label specifies intrathecal infusion by pump and says it is not for intravenous use. Its target, CaV2.2 on pain-sensing afferents in the spinal cord, sits in the dorsal horn.
Are other venom peptides used as drugs?
Yes. Exendin-4 from Gila monster venom led to exenatide, and a peptide from pit-viper venom was the lead for the ACE inhibitor captopril; both are described in drug-discovery histories of venom peptides.
References
- UniProt P05484 — Omega-conotoxin MVIIA (ziconotide), Conus magus
- FDA prescribing information — Prialt (ziconotide) intrathecal infusion, NDA 021060 (2023)
- Olivera BM et al. Peptide neurotoxins from fish-hunting cone snails. Science 1985 (PMID 4071055)
- Olivera BM et al. Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-conotoxin from Conus magus venom. Biochemistry 1987 (PMID 2441741)
- Miljanich GP. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem 2004 (PMID 15578997)
- Gao S, Yao X, Yan N. Structure of human CaV2.2 channel blocked by the painkiller ziconotide. Nature 2021 (PMID 34234349)
- Wikipedia — Conotoxin (overview of toxin families, for orientation)
Informational only — not medical advice. This article is for educational purposes. It does not recommend, sell or instruct personal human use of any compound. Consult a qualified healthcare professional for any health decision. Content is intended for adults 21+. Verify scientific details against the primary sources cited.